2,744 results match your criteria Hepatitis D


Treating chronic hepatitis delta: The need for surrogate markers of treatment efficacy.

J Hepatol 2019 May 27;70(5):1008-1015. Epub 2018 Dec 27.

Department of Gastroenterology and Hepatology, Essen University Hospital, University of Duisburg-Essen, Essen, Germany.

Chronic hepatitis delta represents the most severe form of chronic viral hepatitis. The current treatment of hepatitis delta virus (HDV) infection consists of the use of interferons and is largely unsatisfactory. Several new compounds are currently in development for the treatment of HDV infection. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jhep.2018.12.022DOI Listing
May 2019
1 Read

Evaluation of dried blood spots for hepatitis B and D serology and nucleic acid testing.

J Med Virol 2019 Apr 12. Epub 2019 Apr 12.

Victorian Infectious Diseases Reference Laboratory, Royal Melbourne Hospital and WHO Regional Reference Laboratory for Hepatitis B/D, at The Peter Doherty Institute for Infection and Immunity, Victoria, Australia.

Areas with the highest burden of hepatitis B virus (HBV) infection are often low-middle-income countries with limited access to diagnosis due to isolation, affordability and/or feasibility. Dried blood spots (DBS) provide an alternative for remote areas where collection and transportation of serum is impractical. In this study the application of DBS for serological and molecular detection of HBV and hepatitis D virus (HDV) was evaluated. Read More

View Article

Download full-text PDF

Source
https://onlinelibrary.wiley.com/doi/abs/10.1002/jmv.25485
Publisher Site
http://dx.doi.org/10.1002/jmv.25485DOI Listing
April 2019
5 Reads

Hepatitis D: not a rare disease anymore: global update for 2017-2018.

Gut 2019 Apr 9. Epub 2019 Apr 9.

Department of laboratory Medicine, the First Affiliated Hospital of Nanjing Medical University, Nanjing, China.

View Article

Download full-text PDF

Source
http://gut.bmj.com/lookup/doi/10.1136/gutjnl-2019-318691
Publisher Site
http://dx.doi.org/10.1136/gutjnl-2019-318691DOI Listing
April 2019
6 Reads

Identification of a Novel Deltavirus in Boa Constrictors.

MBio 2019 04 2;10(2). Epub 2019 Apr 2.

Institute of Veterinary Pathology, Vetsuisse Faculty, University of Zurich, Zurich, Switzerland

Hepatitis D virus (HDV) forms the genus unassigned to any virus family. HDV is a satellite virus and needs hepatitis B virus (HBV) to make infectious particles. Deltaviruses are thought to have evolved in humans, since for a long time, they had not been identified elsewhere. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1128/mBio.00014-19DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6445931PMC
April 2019
8 Reads

Hepatitis D reactivation in a patient with metastatic renal cell carcinoma receiving sunitinib therapy.

Tumori 2019 Apr 1:300891619840279. Epub 2019 Apr 1.

2 Department of Medical Oncology, Bakırkoy Dr. Sadi Konuk Training and Research Hospital, University of Health Sciences, Faculty of Medicine, Bakirkoy, Istanbul, Turkey.

Background:: Cytotoxic and immunosuppressive therapies for cancer treatment may allow hepatitis reactivation. Hepatitis due to viral hepatitis reactivation is detected in 14%-25% of hepatitis B surface antigen (HBsAg)-positive cancer patients undergoing anticancer treatments. Drug toxicity may be confused with hepatitis reactivation, which may cause a delay in diagnosis. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1177/0300891619840279DOI Listing
April 2019
5 Reads

Hepatitis D virus infection in patients with hepatitis B virus occult infection.

Eur J Gastroenterol Hepatol 2019 05;31(5):646

Institute of Research in Medical Microbiology and Parasitology, University of Buenos Aires-National Council of Scientific and Technical Research, Autonomous City of Buenos Aires, Argentina.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/MEG.0000000000001362DOI Listing
May 2019
4 Reads

AMSSM Position Statement Update: Blood-Borne Pathogens in the Context of Sports Participation.

Clin J Sport Med 2019 Mar 20. Epub 2019 Mar 20.

Oregon Health Sciences University, Portland, Oregon.

This AMSSM position statement update is directed toward health care providers of patients involved in sport and exercise. There have been significant advances in clinical and scientific research in the understanding of blood-borne pathogens (BBPs), and this update incorporates these advancements. This document is intended as a general guide to clinical practice based on the current state of evidence, while acknowledging the need for modification as new knowledge becomes available. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/JSM.0000000000000738DOI Listing
March 2019
10 Reads

Early Multiphasic HBV Infection Initiation Kinetics Is Not Clone-Specific and Is Not Affected by Hepatitis D Virus (HDV) Infection.

Viruses 2019 Mar 15;11(3). Epub 2019 Mar 15.

Department of Gastroenterology and Metabolism, Graduate School of Biomedical & Health Sciences, Hiroshima University, Hiroshima 734-8551, Japan.

We previously demonstrated that serum hepatitis B virus (HBV) DNA in HBV infected humanized mice exhibited a highly dynamic multiphasic kinetic pattern from infection initiation to steady-state. Here, we investigated whether this pattern is consistent across different HBV clones or in the presence of hepatitis D virus (HDV) co-infection. We analyzed early serum viral kinetics using 26 HBV genotype C (GtC) mono-infected mice [clones: PXB, Hiroshima GtC CL4 (CL4) and Hiroshima GtC CL5 (CL5)] and four HBV CL4/HDV genotype one co-infected mice. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3390/v11030263DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6466026PMC
March 2019
1 Read

Current state-of-the-art pharmacotherapy for the management of hepatitis B infection.

Expert Opin Pharmacother 2019 May 11;20(7):873-885. Epub 2019 Mar 11.

a Department of Medicine, Division of Gastroenterology, Hepatology and Nutrition, Brody School of Medicine , East Carolina University , Greenville , NC , USA.

Introduction: Hepatitis B virus (HBV) infection remains a global challenge with several hundred million infected individuals. Disease activity can be controlled, and adverse outcomes prevented when treatment can be provided. Frequently life-long therapy is required instead of defined treatment periods such as with the case of Hepatitis C Virus (HCV) infection. Read More

View Article

Download full-text PDF

Source
https://www.tandfonline.com/doi/full/10.1080/14656566.2019.1
Publisher Site
http://dx.doi.org/10.1080/14656566.2019.1583744DOI Listing
May 2019
3 Reads

Combined small molecule and loss-of-function screen uncovers estrogen receptor alpha and CAD as host factors for HDV infection and antiviral targets.

Gut 2019 Mar 4. Epub 2019 Mar 4.

Université de Strasbourg, Inserm, Institut de Recherche sur les Maladies Virales et Hépatiques UMR_S1110, F-67000 Strasbourg, France.

Objective: Hepatitis D virus (HDV) is a circular RNA virus coinfecting hepatocytes with hepatitis B virus. Chronic hepatitis D results in severe liver disease and an increased risk of liver cancer. Efficient therapeutic approaches against HDV are absent. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1136/gutjnl-2018-317065DOI Listing
March 2019
6 Reads

Hepatitis D virus infection among hepatitis B virus surface antigen positive individuals in Upper Egypt: Prevalence and clinical features.

J Infect Public Health 2018 Dec 23. Epub 2018 Dec 23.

Department of Clinical Pathology, Faculty of Medicine, Assiut University, Assiut 71515, Egypt. Electronic address:

Background/purpose: About 248 million people are chronic HBV surface antigen carriers in the world. Hepatitis D virus (HDV) infection present in more than 15 million people worldwide. HDV needs hepatitis B surface antigen (HBsAg) to help its replication. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jiph.2018.12.001DOI Listing
December 2018
1 Read

Peginterferon alfa-2a plus tenofovir disoproxil fumarate for hepatitis D (HIDIT-II): a randomised, placebo controlled, phase 2 trial.

Lancet Infect Dis 2019 Mar;19(3):275-286

Department of Gastroenterology, Hepatology and Endocrinology, Hannover Medical School, Hannover, Germany; German Center for Infectious Disease Research, HepNet Study-House, Hannover, Germany.

Background: Hepatitis D is the most severe form of chronic viral hepatitis. Treatment guidelines recommend 1 year of peginterferon alfa, which is effective in 25-30% of patients only. Whether prolonged therapy with peginterferon alfa-2a for 96 weeks and combination therapy with tenofovir disoproxil fumarate (TDF) would increase hepatitis D virus (HDV) RNA suppression is unknown. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/S1473-3099(18)30663-7DOI Listing
March 2019
4 Reads

Viral hepatitis: Guidelines by the American Society of Transplantation Infectious Disease Community of Practice.

Clin Transplant 2019 Feb 28:e13514. Epub 2019 Feb 28.

Division of Infectious Diseases, University of Alberta, Edmonton, Alberta, Canada.

These updated guidelines from the Infectious Diseases Community of Practice of the American Society of Transplantation review the diagnosis, prevention, and management of viral hepatitis in the pre- and post-transplant period. The current guidelines reflect the declining need for hepatitis B immunoglobulin following liver transplant, now replaced with nucleos(t)ide analogues that effectively suppress viral replication for the long term with minimal risk for drug resistance. It describes the limitations of pegylated interferon alpha in the treatment for chronic hepatitis D. Read More

View Article

Download full-text PDF

Source
http://doi.wiley.com/10.1111/ctr.13514
Publisher Site
http://dx.doi.org/10.1111/ctr.13514DOI Listing
February 2019
3 Reads

Genetic diversity of hepatitis D virus genotype-1 in Europe allows classification into subtypes.

J Viral Hepat 2019 Feb 23. Epub 2019 Feb 23.

Institute of Virology, Technische Universität München, Munich, Germany.

Hepatitis delta virus (HDV) is an RNA virus which leads to both acute and chronic forms of hepatitis. At present, HDV isolates have been classified into eight major genotypes distributed over different geographical regions. Recent increase in HDV sequences in Europe and worldwide has enabled us to revisit the taxonomic classification of HDV. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/jvh.13086DOI Listing
February 2019
1 Read

Antiviral treatment with pegylated interferon and clinical outcomes in a cohort of immigrants patients affected by hepatitis delta: A retrospective analysis.

J Med Virol 2019 Feb 22. Epub 2019 Feb 22.

Unit of Infectious Diseases, Department of Medical Sciences, Amedeo di Savoia Hospital, University of Turin, Turin, Italy.

Chronic hepatitis delta (CHD) is the most severe chronic hepatitis, with no satisfactory treatment options and severe clinical outcomes. This infection is frequent in the migrant subjects from endemic areas, especially from Africa and East-Europe. The pegylated (PEG)-interferon α (IFN) is limited by side effects and poor response. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/jmv.25438DOI Listing
February 2019
6 Reads

Clinical outcomes in patients with hepatitis D, cirrhosis and persistent hepatitis B virus replication, and receiving long-term tenofovir or entecavir.

Aliment Pharmacol Ther 2019 Apr 21;49(8):1071-1076. Epub 2019 Feb 21.

Infectious Diseases, Campania University "Luigi Vanvitelli", Naples, Italy.

Background: Suppression of hepatitis B virus (HBV) replication with nucelos(t)ide analogues should be considered for patients with chronic hepatitis D virus (HDV) infection and ongoing HBV replication.

Aim: To verify the clinical outcome after long-term entecavir or tenofovir treatment in patients with advanced fibrosis/cirrhosis, ineligible to peg-interferon therapy.

Methods: Patients were prospectively followed-up at 3-6 month intervals; measured outcomes were decompensation, hepatocellular carcinoma (HCC), liver transplant and liver related death. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/apt.15188DOI Listing
April 2019
1 Read

New treatment options for delta virus: Is a cure in sight?

Authors:
Cihan Yurdaydin

J Viral Hepat 2019 Feb 16. Epub 2019 Feb 16.

Department of Gastroenterology, Ankara University Medical School, Ankara, Turkey.

Current treatment of chronic hepatitis D viral infection with interferons is poorly tolerated and effective only in a minority of patients. Despite delta virus causing the most severe form of chronic viral hepatitis, no other treatments are available. After many years of inactivity, there is now hope for new treatment approaches for delta virus and some are likely to enter clinical practice in the near future. Read More

View Article

Download full-text PDF

Source
http://doi.wiley.com/10.1111/jvh.13081
Publisher Site
http://dx.doi.org/10.1111/jvh.13081DOI Listing
February 2019
7 Reads

Mutations in Hepatitis D Virus Allow It to Escape Detection by CD8 T Cells and Evolve at the Population Level.

Gastroenterology 2019 May 12;156(6):1820-1833. Epub 2019 Feb 12.

Department of Medicine II, University Hospital Freiburg, Faculty of Medicine, University of Freiburg, Freiburg, Germany. Electronic address:

Background & Aims: Hepatitis D virus (HDV) superinfection in patients with hepatitis B virus (HBV) is associated with rapid progression to liver cirrhosis and hepatocellular carcinoma. Treatment options are limited, and no vaccine is available. Although HDV-specific CD8 T cells are thought to control the virus, little is known about which HDV epitopes are targeted by virus-specific CD8 T cells or why these cells ultimately fail to control the infection. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1053/j.gastro.2019.02.003DOI Listing
May 2019
7 Reads
16.716 Impact Factor

Epidemiology of viral hepatitis in the Maghreb.

Tunis Med 2018 Oct-Nov;96(10-11):606-619

Introduction: Viral hepatitis represents a serious public health problem in the world especially in the Maghreb where the prevalence of the 5 viruses A, B, C, D, and E remains high and varies from one Maghreb country to another, there is few published studies on these infections in our Maghreb countries.

Method Of Study: Our work is a review of the literature about prevalence, the most common mode of transmission, and the most exposed population for these viruses in the Maghreb countries through published studies between 2011 and 2017.

Result: It has been found that the Maghreb countries are endemic for the five viruses with variable prevalence from one country to another, with sometimes heterogeneous data in the same country. Read More

View Article

Download full-text PDF

Source
February 2019
2 Reads

Hepatitis Delta Prevalence in South America: A Systematic Review and Meta-Analysis.

Rev Soc Bras Med Trop 2019 Jan 24;52:e20180289. Epub 2019 Jan 24.

Diretoria de Pesquisa e Desenvolvimento. Fundação Ezequiel Dias, Belo Horizonte, MG, Brasil.

Hepatitis delta virus (HDV) has been associated with acute or chronic hepatitis in Latin America, but there is no prevalence study covering South American countries. This meta-analysis aimed to estimate anti-HDV prevalence through a systematic review of published articles in English, Portuguese and Spanish until December 2017. Searches were conducted in Health Virtual Library, Capes, Lilacs, PubMed, and SciELO, according to defined criteria regarding participant selection and geographical setting. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1590/0037-8682-0289-2018DOI Listing
January 2019
4 Reads

Hepatitis D - how is the fight against this foe going?

Expert Rev Clin Pharmacol 2019 Mar 6;12(3):169-171. Epub 2019 Feb 6.

a CRC "A. M. and A. Migliavacca" Center for the Study of Liver Disease, Division of Gastroenterology and Hepatology , Fondazione IRCCS Cà Granda Ospedale Maggiore Policlinico, Università degli Studi di Milano , Milan , Italy.

View Article

Download full-text PDF

Source
https://www.tandfonline.com/doi/full/10.1080/17512433.2019.1
Publisher Site
http://dx.doi.org/10.1080/17512433.2019.1577135DOI Listing
March 2019
16 Reads

Non-F HBV/HDV-3 coinfection is associated with severe liver disease in Western Brazilian Amazon.

J Med Virol 2019 Jun 11;91(6):1081-1086. Epub 2019 Feb 11.

Institut National de la Santé et de la Recherche Medicale, INSERM U1052, Lyon, France.

The clinical outcome of hepatitis B virus (HBV) infection may be related to host and viral genetic factors, as well as to the type of infection (monoinfection and coinfection). To analyze the distribution/combination of HBV/hepatitis D virus (HDV) genotypes and the associated clinical characteristics, 409 serum samples from patients with chronic HBV (94 of them coinfected by HDV) followed at the Viral Hepatitis Referral Center of Rio Branco, Brazil were enrolled. HBV DNA and HDV RNA were amplified, respectively, by polymerase chain reaction (PCR) and nested PCR using specific primers in the PreC/C region and the S gene, and by reverse-transcription PCR and seminested PCR using specific primers in the delta antigen region and sequenced. Read More

View Article

Download full-text PDF

Source
http://doi.wiley.com/10.1002/jmv.25411
Publisher Site
http://dx.doi.org/10.1002/jmv.25411DOI Listing
June 2019
12 Reads

The balance of type 1 and type 2 immune responses in the contexts of hepatitis B infection and hepatitis D infection.

J Gastroenterol Hepatol 2019 Apr 25;34(4):764-775. Epub 2019 Feb 25.

Liver Diseases Branch, National Institute of Diabetes, Digestive, and Kidney Diseases, Bethesda, Maryland, USA.

Background And Aim: Hepatitis delta virus (HDV) infection is the most rapidly progressive chronic viral hepatitis. Little is understood about the immune responses to HDV. This study aims to characterize the systemic immune environments of hepatitis B virus (HBV) and HDV patients at various disease stages. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/jgh.14617DOI Listing
April 2019
5 Reads

Hepatitis D Virus-Specific CD8 T Cells Have a Memory-Like Phenotype Associated With Viral Immune Escape in Patients With Chronic Hepatitis D Virus Infection.

Gastroenterology 2019 May 18;156(6):1805-1819.e9. Epub 2019 Jan 18.

Immunology Section, Liver Diseases Branch, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, US Department of Health and Human Services, Bethesda, Maryland. Electronic address:

Background & Aim: Hepatitis D virus (HDV) superinfection of patients with chronic HBV infection results in rapid progression to liver cirrhosis. Little is known about HDV-specific T cells and how they contribute to the antiviral immune response and liver disease pathogenesis.

Methods: We isolated peripheral blood mononuclear cells from 28 patients with chronic HDV and HBV infection, identified HDV-specific CD8 T-cell epitopes, and characterized HDV-specific CD8 T cells. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1053/j.gastro.2019.01.035DOI Listing
May 2019
5 Reads

Hepatitis D virus infection, cirrhosis and hepatocellular carcinoma in The Gambia.

J Viral Hepat 2019 Jan 20. Epub 2019 Jan 20.

Division of Cancer Epidemiology and Genetics, National Cancer Institute, Rockville, Maryland.

Hepatocellular carcinoma (HCC) incidence is high in The Gambia, and hepatitis B virus (HBV) infection is the main cause. People coinfected with HBV and hepatitis D virus (HDV) have an even greater risk of HCC and cirrhosis. Using a new HDV quantitative microarray antibody capture (Q-MAC) assay, we evaluated the association between HDV infection and HCC or cirrhosis among participants in The Gambia Liver Cancer Study. Read More

View Article

Download full-text PDF

Source
http://doi.wiley.com/10.1111/jvh.13065
Publisher Site
http://dx.doi.org/10.1111/jvh.13065DOI Listing
January 2019
13 Reads
3.909 Impact Factor

Towards curative therapy of chronic viral hepatitis.

Z Gastroenterol 2019 Jan 14;57(1):61-73. Epub 2019 Jan 14.

Institut für Virologie, Technische Universität München.

Persistent infection with hepatitis viruses is a major medical burden that unfortunately is often ignored in the general public. This results in a massive under-diagnosis of these infections. According to the world health organization, the number of people dying every year from the consequence of hepatitis virus infection has surpassed the death rate caused by malaria and HIV and is equivalent to the one of tuberculosis. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1055/a-0824-1576DOI Listing
January 2019
12 Reads

Prevalence of Hepatitis B and Hepatitis D Virus Infections in the United States, 2011-2016.

Clin Infect Dis 2019 Jan 3. Epub 2019 Jan 3.

Dept. of Pathology, Johns Hopkins University School of Medicine, Baltimore, MD, USA.

In the U.S. household population aged 18 years (2011-2016), prevalence of hepatitis B surface antigen (HBsAg) was 0. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/cid/ciz001DOI Listing
January 2019
3 Reads

Hepatitis B, C, and D virus and human T-cell leukemia virus types 1 and 2 infections and correlates among men who have sex with men in Ouagadougou, Burkina Faso.

Virol J 2018 12 29;15(1):194. Epub 2018 Dec 29.

University Ouaga1 Joseph Ki-Zerbo, Ouagadougou, Burkina Faso.

Background: Men who have sex with men (MSM) are considered to be at significant risk for sexually transmitted infections (STI) and bloodborne viruses including viral hepatitis types B, C, and D (HBV, HCV, and HDV) and human T-cell leukemia virus types 1 and 2 (HTLV 1&2). This study aimed to assess the seroprevalence and correlates of HBV, HCV, HDV, and HTLV 1&2 antibodies among MSM in Ouagadougou, Burkina Faso.

Methods: We conducted a cross-sectional survey to assess the biological and behavourial characteristics among MSM in Ouagadougou from January to April 2013. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s12985-018-1110-8DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6311018PMC
December 2018
6 Reads

Rates of HBV, HCV, HDV and HIV type 1 among pregnant women and HIV type 1 drug resistance-associated mutations in breastfeeding women on antiretroviral therapy.

BMC Pregnancy Childbirth 2018 Dec 22;18(1):504. Epub 2018 Dec 22.

Faculty of Medicine and Biomedical Sciences, University of Yaounde I, Yaounde, Cameroon.

Background: HBV, HCV, HDV and HIV are blood borne and can be transmitted from mother-to-child. Reports of HBV infection rates show up to 11.9% in Cameroon while for HCV, the rate is less than 2%. Read More

View Article

Download full-text PDF

Source
https://bmcpregnancychildbirth.biomedcentral.com/articles/10
Publisher Site
http://dx.doi.org/10.1186/s12884-018-2120-7DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6303885PMC
December 2018
14 Reads

INASL Guidelines on Management of Hepatitis B Virus Infection in Patients receiving Chemotherapy, Biologicals, Immunosupressants, or Corticosteroids.

J Clin Exp Hepatol 2018 Dec 26;8(4):403-431. Epub 2018 Jun 26.

Hepatology & Liver Transplant (Medicine), Fortis Escorts Liver & Digestive Diseases Institute (FELDI), Fortis Escorts Hospital, Delhi, India.

Hepatitis B Virus (HBV) reactivation in patients receiving chemotherapy, biologicals, immunosupressants, or corticosteroids is emerging to be an important cause of morbidity and mortality in patients with current or prior exposure to HBV infection. These patients suffer a dual onslaught of illness: one from the primary disease for which they are receiving the culprit drug that led to HBV reactivation, and the other from HBV reactivation itself. The HBV reactivation not only leads to a compromised liver function, which may culminate into hepatic failure; it also adversely impacts the treatment outcome of the primary illness. Read More

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S09736883183009
Publisher Site
http://dx.doi.org/10.1016/j.jceh.2018.06.010DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6286881PMC
December 2018
34 Reads

Hepatitis D prevalence: problems with extrapolation to global population estimates.

Gut 2018 Dec 19. Epub 2018 Dec 19.

Institute of Infection and Global Health, University of Liverpool, Liverpool, UK.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1136/gutjnl-2018-317874DOI Listing
December 2018
5 Reads

A Divergent Hepatitis D-Like Agent in Birds.

Viruses 2018 12 17;10(12). Epub 2018 Dec 17.

WHO Collaborating Centre for Reference and Research on Influenza, The Peter Doherty Institute for Infection and Immunity, Melbourne, VIC 3000, Australia.

Hepatitis delta virus (HDV) is currently only found in humans and is a satellite virus that depends on hepatitis B virus (HBV) envelope proteins for assembly, release, and entry. Using meta-transcriptomics, we identified the genome of a novel HDV-like agent in ducks. Sequence analysis revealed secondary structures that were shared with HDV, including self-complementarity and ribozyme features. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3390/v10120720DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6315422PMC
December 2018
2 Reads

A Brief Update on the Management of Hepatitis Delta.

Curr Gastroenterol Rep 2018 Dec 14;20(12):60. Epub 2018 Dec 14.

Loyola University Medical Center, 2160 S First Ave., Maywood, IL, 60153, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s11894-018-0666-1DOI Listing
December 2018
1 Read

Epidemiology and clinical management of HIV-HBV coinfected patients in a large AIDS Reference Center in Belgium.

Acta Clin Belg 2018 Dec 4:1-6. Epub 2018 Dec 4.

b Department of Infectious Diseases , Saint-Pierre University Hospital , Brussels ,
 Belgium.

Objectives: Human immunodeficiency virus (HIV) and hepatitis B virus (HBV) are both worldwide health concerns with similar routes of transmission and no curative treatment to date. Coinfection is associated with increased morbidity and mortality. We aim to provide epidemiological data about HIV-HBV coinfected patients and asses if management of patients following European recommendation (EACS) was achieved in a large AIDS Reference Center in Belgium. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/17843286.2018.1554292DOI Listing
December 2018
3 Reads

[Hepatitis delta virus replication and the role of the small hepatitis delta protein S-HDAg].

Med Sci (Paris) 2018 Oct 19;34(10):833-841. Epub 2018 Nov 19.

Inserm, U1052 - UMR CNRS 5286, Centre de recherche en cancérologie de Lyon, Lyon, France - Laboratoire de microbiologie clinique, groupe des Hôpitaux universitaires de Paris-Seine Saint Denis, UFR santé médecine, biologie humaine, université Paris 13, Bobigny, France.

Hepatitis delta virus (HDV) is a mammalian defective virus. Its genome is a small single-stranded circular RNA of approximately 1,680 nucleotides. To spread, HDV relies on hepatitis B virus envelope proteins that are needed for viral particle assembly and egress. Read More

View Article

Download full-text PDF

Source
https://www.medecinesciences.org/10.1051/medsci/2018209
Publisher Site
http://dx.doi.org/10.1051/medsci/2018209DOI Listing
October 2018
29 Reads

HDV evolution-will viral resistance be an issue in HDV infection?

Curr Opin Virol 2018 10 8;32:100-107. Epub 2018 Nov 8.

Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBERehd), Instituto de Salud Carlos III, 28029 Madrid, Spain; Liver Pathology Unit, Departments of Biochemistry and Microbiology, Hospital Universitari Vall d'Hebron, Universitat Autònoma de Barcelona (UAB), 08035 Barcelona, Spain. Electronic address:

Hepatitis D virus (HDV) is a hepatotropic subviral infectious agent, obligate satellite of the Hepatitis B virus (HBV) and is highly related to viroids. HDV affects around 5% of the 257 million chronic HBV-carriers worldwide, leading to the most severe form of chronic viral hepatitis. Interferon alpha is the only approved treatment for chronic hepatitis D, albeit with low response rates (around 20%-30%). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.coviro.2018.10.003DOI Listing
October 2018
3 Reads

Delta hepatitis in resolved hepatitis B.

Eur J Gastroenterol Hepatol 2018 12;30(12):1528

Unit of Gastroenterology, Department of Medical, Surgical and Neurological Sciences, University of Siena, Siena, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/MEG.0000000000001253DOI Listing
December 2018
17 Reads

The influence of ethnicity on disease outcome in patients with chronic hepatitis B infection.

J Med Virol 2019 Apr 28;91(4):623-629. Epub 2018 Nov 28.

School of Nutrition and Translational Research in Metabolism, University Maastricht, Maastricht, The Netherlands.

Since the cultural diversity in Western Europe is growing, this study assessed whether foreign-born chronic hepatitis B (CHB) patients have more cirrhosis than Dutch- or Belgian-born patients, with a main focus on the Turkish population. Baseline characteristics (eg, socioeconomic status [SES]), biological characteristics, and disease outcome (eg, cirrhosis) were collected for all patients. Between December 2009 and January 2015, 269 CHB patients participated from the outpatient departments of three hospitals in the Netherlands, Belgium, and Turkey. Read More

View Article

Download full-text PDF

Source
http://doi.wiley.com/10.1002/jmv.25353
Publisher Site
http://dx.doi.org/10.1002/jmv.25353DOI Listing
April 2019
8 Reads

Anti-HDV seroprevalance among patients with previous HBV infection.

North Clin Istanb 2018 21;5(2):132-138. Epub 2018 May 21.

Department of Internal Medicine, Faculty of Medicine, Firat University, Division of Gastroenterology, Elazig, Turkey.

Objective: This prospective study aimed to determine the prevalence of anti-HDV seropositivity among subjects who had previous hepatitis B virus (HBV) infection.

Methods: Subjects who were admitted to the gastroenterology inpatient clinic of our hospital between August 2016 and July 2017 were screened for previous HBV infection. The subjects who had HBV serology compatible with resolved HBV infection were recruited in the study, and the seroprevalance of anti-HDV was studied. Read More

View Article

Download full-text PDF

Source
http://www.kuzeyklinikleri.com/jvi.aspx?pdir=nci&plng=en
Publisher Site
http://dx.doi.org/10.14744/nci.2018.01328DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6191552PMC
May 2018
37 Reads

Devil hepatitis D: an orphan disease or largely underdiagnosed?

Gut 2018 Oct 27. Epub 2018 Oct 27.

Divisions of Gastroenterology and Hepatology of Clinical Pathology, University Hospital of Geneva, Geneva, Switzerland.

View Article

Download full-text PDF

Source
http://gut.bmj.com/lookup/doi/10.1136/gutjnl-2018-317403
Publisher Site
http://dx.doi.org/10.1136/gutjnl-2018-317403DOI Listing
October 2018
14 Reads

The Epidemiology of Hepatitis D Virus in North Africa: A Systematic Review and Meta-Analysis.

ScientificWorldJournal 2018 26;2018:9312650. Epub 2018 Sep 26.

Department of Planning, Faculty of Engineering, University of Tripoli, CC 82668, Tripoli, Libya.

Background: Hepatitis D virus (HDV) infection has been considered a serious neglected pandemic, particularly in developing countries. The virus causes a more severe disease than mono infection with hepatitis B virus (HBV). The epidemiology of HDV is not well documented in North Africa, which is known to be endemic for HBV. Read More

View Article

Download full-text PDF

Source
https://www.hindawi.com/journals/tswj/2018/9312650/
Publisher Site
http://dx.doi.org/10.1155/2018/9312650DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6178169PMC
January 2019
20 Reads

Pathogenesis of and New Therapies for Hepatitis D.

Gastroenterology 2019 01 18;156(2):461-476.e1. Epub 2018 Oct 18.

Division of Gastroenterology and Hepatology, Stanford University School of Medicine, Stanford, California. Electronic address:

Hepatitis delta virus (HDV) infection of humans was first reported in 1977, and now it is now estimated that 15-20 million people are infected worldwide. Infection with HDV can be an acute or chronic process that occurs only in patients with an hepatitis B virus infection. Chronic HDV infection commonly results in the most rapidly progressive form of viral hepatitis; it is the chronic viral infection that is most likely to lead to cirrhosis, and it is associated with an increased risk of hepatocellular carcinoma. Read More

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S00165085183516
Publisher Site
http://dx.doi.org/10.1053/j.gastro.2018.09.058DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6340762PMC
January 2019
20 Reads

Epidemiology of hepatitis B, C and D in Malawi: systematic review.

BMC Infect Dis 2018 Oct 12;18(1):516. Epub 2018 Oct 12.

Malawi Liverpool Wellcome Trust Clinical Research Programme, Chichiri 3, PO Box 30096, Blantyre, Malawi.

Background: Viral hepatitis is an important public health issue in sub-Saharan Africa. Due to rising mortality from cirrhosis and hepatocellular carcinoma and limited implementation of screening and treatment programmes, it has been characterised as a neglected tropical disease. Synthesis of the existing evidence on the epidemiology of viral hepatitis B, C and D in Malawi is required to inform policy and identify research gaps. Read More

View Article

Download full-text PDF

Source
https://bmcinfectdis.biomedcentral.com/articles/10.1186/s128
Publisher Site
http://dx.doi.org/10.1186/s12879-018-3428-7DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6186098PMC
October 2018
3 Reads

Multiple chronic parasitic infections in an immunocompetent immigrant: a challenge for healthcare management.

Infez Med 2018 Sep;26(3):276-279

Dipartimento di Biotecnologie Mediche, Università di Siena, Siena, Italy; UOC Malattie Infettive Universitarie, AOUS, Siena, Italy.

The case reports multiple helmintiasis and chronic hepatitis caused by hepatitis B virus (HBV)/hepatitis D virus (HDV) in an immunocompetent immigrant male. It highlights the importance of early diagnosis and treatment of neglected infectious diseases in low endemic areas, besides difficulties that Western countries encounter in responding to immigrants' health needs. Read More

View Article

Download full-text PDF

Source
September 2018
5 Reads

Transmission of Hepatitis B and D Viruses in an African Rural Community.

mSystems 2018 Sep-Oct;3(5). Epub 2018 Sep 18.

Swiss Tropical and Public Health Institute, Molecular Immunology, Basel, Switzerland.

According to the World Health Organization (WHO), an estimated 257 million people worldwide are chronically infected with hepatitis B virus (HBV), with approximately 15 million of them being coinfected with hepatitis D virus (HDV). To investigate the prevalence and transmission of HBV and HDV within the general population of a rural village in Cameroon, we analyzed serum samples from most (401/448) of the villagers. HBV surface antigen (HBsAg) was detected in 54 (13. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1128/mSystems.00120-18DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6143728PMC
September 2018
7 Reads

Epidemiology of viral hepatitis in Somalia: Systematic review and meta-analysis study.

World J Gastroenterol 2018 Sep;24(34):3927-3957

Center For the study of the Liver, Department of Hospital Medicine, Peoples' Friendship University of Russia (RUDN University), Moscow 117198, Russia.

Aim: To provide a clear understanding of viral hepatitis epidemiology and their clinical burdens in Somalia.

Methods: A systematic review and meta-analysis was conducted as Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines. A comprehensive literature search of published studies on viral hepatitis was performed from 1977-2016 in PubMed, Google Scholar, Science Direct, World Health Organization African and the Africa Journals Online databases, as well as on the Ministry of Health website. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3748/wjg.v24.i34.3927DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6141335PMC
September 2018
7 Reads

Prevalence and burden of hepatitis D virus infection in the global population: a systematic review and meta-analysis.

Gut 2018 Sep 18. Epub 2018 Sep 18.

Department of Laboratory Medicine, The First Affiliated Hospital of Nanjing Medical University, Nanjing, China.

Objective: Hepatitis D virus (HDV) is a defective virus that completes its life cycle only with hepatitis B virus (HBV). The HBV with HDV super-infection has been considered as one of the most severe forms of the chronic viral hepatitis. However, there is a scarcity of data on the global burden of HDV infection. Read More

View Article

Download full-text PDF

Source
http://gut.bmj.com/lookup/doi/10.1136/gutjnl-2018-316601
Publisher Site
http://dx.doi.org/10.1136/gutjnl-2018-316601DOI Listing
September 2018
6 Reads
14.660 Impact Factor

REP 2139: Antiviral Mechanisms and Applications in Achieving Functional Control of HBV and HDV Infection.

Authors:
Andrew Vaillant

ACS Infect Dis 2018 Oct 5. Epub 2018 Oct 5.

Replicor Inc. , 6100 Royalmount Avenue , Montreal , Quebec H4P 2R2 , Canada.

Nucleic acid polymers (NAPs) are broad spectrum antiviral agents whose antiviral activity in hepatitis B virus (HBV) infection is derived from their ability to block the release of the hepatitis B virus surface antigen (HBsAg). This pharmacological activity blocks replenishment of HBsAg in the circulation, allowing host mediated clearance. This effect has important clinical significance as the clearance of circulating HBsAg dramatically potentiates the ability of immunotherapies to restore functional control of HBV infection which persists after antiviral therapy is removed. Read More

View Article

Download full-text PDF

Source
http://pubs.acs.org/doi/10.1021/acsinfecdis.8b00156
Publisher Site
http://dx.doi.org/10.1021/acsinfecdis.8b00156DOI Listing
October 2018
2 Reads

Screening for hepatitis D and PEG-Interferon over Tenofovir enhance general hepatitis control efforts in Brazil.

PLoS One 2018 7;13(9):e0203831. Epub 2018 Sep 7.

Theoretical Biology and Biophysics, Los Alamos National Laboratory, Los Alamos, New Mexico, United States of America.

Background: Hepatitis D virus (HDV), which requires the presence of hepatitis B virus (HBV), is a deadly yet neglected disease that rapidly leads to liver cancer and disease-induced mortality. This co-dependence creates complex transmission dynamics that make it difficult to predict the efficacy of interventions aimed at HBV and/or HDV control in endemic regions, such as certain municipalities of Brazil, where up to 65% of HBV-infected persons are co-infected.

Methodology: We created a mathematical model that captures the joint transmission dynamics of HBV and HDV, incorporating mother-to-child, sexual and household transmission. Read More

View Article

Download full-text PDF

Source
http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0203831PLOS
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6128631PMC
March 2019
1 Read